{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:37:37Z","timestamp":1787841457226,"version":"build-2784847793"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073321"],"award-info":[{"award-number":["82073321"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tyrosine kinase inhibitors (TKIs) alone and in combination with immune checkpoint inhibitors (ICIs) have been shown to be beneficial for the survival of metastatic renal cell carcinoma (mRCC) patients, but resistance to targeted therapy and ICIs is common in the clinic. Understanding the underlying mechanism is critical for further prolonging the survival of renal cancer patients. Nuclear factor of activated T cell 1 (NFAT1) is expressed in immune and nonimmune cells, and the dysregulation of NFAT1 contributes to the progression of various type of malignant tumors. However, the specific role of NFAT1 in RCC is elusive. As a regulator of the immune response, we would like to systemically study the role of NFAT1 in RCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>TCGA-KIRC dataset analysis, Western blot analysis and RT-qPCR analysis was used to determine the clinic-pathological characteristic of NFAT1 in RCC. CCK-8 assays, colony formation assays and xenograft assays were performed to examine the biological role of NFAT1 in renal cancer cells. RNA-seq analysis was used to examine the pathways changed after NFAT1 silencing. ChIP-qPCR, coimmunoprecipitation analysis, Western blot analysis and RT-qPCR analysis were applied to explore the mechanism by NAFT1 was regulated in the renal cancer cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our study, we found that NFAT1 was abnormally overexpressed in RCC and that NFAT1 overexpression was associated with an unfavorable prognosis. Then, we showed that NFAT1 enhanced tumor growth and regulated the immune response by increasing PD-L1 expression in RCC. In addition, we demonstrated that NFAT1 was stabilized in sunitinib-resistant RCC via hyperactivation of the PI3K\/AKT\/GSK-3\u03b2 signaling pathway. Furthermore, our study indicated that downregulation of the expression of FBW7, which promotes NFAT1 degradation, was induced by FOXA1 and SETD2 in sunitinib-resistant RCC. Finally, FBW7 was found to contribute to modulating the immune response in RCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data reveal a novel role for the FBW7\/NFAT1 axis in the RCC response to TKIs and ICIs. NFAT1 and its associated signaling pathway might be therapeutic targets for RCC treatment, especially when combined with ICIs and\/or TKIs.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13046-022-02253-0","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T09:02:34Z","timestamp":1643187754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A novel FBW7\/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression"],"prefix":"10.1186","volume":"41","author":[{"given":"Wentao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianyun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6461-6005","authenticated-orcid":false,"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"2253_CR1","volume-title":"GLOBOCAN. Kidney\u2014estimated incidence, all ages: both sexes","author":"International Agency for Research on Cancer","year":"2012","unstructured":"International Agency for Research on Cancer. GLOBOCAN. Kidney\u2014estimated incidence, all ages: both sexes. 2012 http:\/\/globocan.iarc.fr\/old\/summary_table_site-html.asp?selection=10210&title=Kidney&sex=0&type=0&window=1&africa=1&america=2&asia=3&europe=4&oceania=5&build=6&sort=0&submit=%C2%A0Execute%C2%A0."},{"key":"2253_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2253_CR3","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdw241","volume":"27","author":"N Shenoy","year":"2016","unstructured":"Shenoy N, Pagliaro L. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. Ann Oncol. 2016;27:1685\u201395.","journal-title":"Ann Oncol"},{"key":"2253_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.kint.2020.08.028","volume":"99","author":"X Wang","year":"2021","unstructured":"Wang X, Lopez R, Luchtel RA, Hafizi S, Gartrell B, Shenoy N. Immune evasion in renal cell carcinoma: biology, clinical translation, future directions. Kidney Int. 2021;99:75\u201385.","journal-title":"Kidney Int"},{"key":"2253_CR5","doi-asserted-by":"crossref","first-page":"g4797","DOI":"10.1136\/bmj.g4797","volume":"349","author":"E Jonasch","year":"2014","unstructured":"Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. 2014;349:g4797.","journal-title":"BMJ"},{"key":"2253_CR6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865\u201375.","journal-title":"N Engl J Med"},{"key":"2253_CR7","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530\u201340.","journal-title":"J Clin Oncol"},{"key":"2253_CR8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913\u201324.","journal-title":"Eur Urol"},{"key":"2253_CR9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2017.82","volume":"13","author":"EM Posadas","year":"2017","unstructured":"Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13:496\u2013511.","journal-title":"Nat Rev Nephrol"},{"key":"2253_CR10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116\u201327.","journal-title":"N Engl J Med"},{"key":"2253_CR11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103\u201315.","journal-title":"N Engl J Med"},{"key":"2253_CR12","first-page":"297","volume":"1846","author":"JJ Qin","year":"2014","unstructured":"Qin JJ, Nag S, Wang W, Zhou J, Zhang WD, Wang H, et al. NFAT as cancer target: mission possible? Biochim Biophys Acta. 2014;1846:297\u2013311.","journal-title":"Biochim Biophys Acta"},{"key":"2253_CR13","doi-asserted-by":"crossref","first-page":"8907","DOI":"10.1073\/pnas.93.17.8907","volume":"93","author":"C Luo","year":"1996","unstructured":"Luo C, Shaw KT, Raghavan A, Aramburu J, Garcia-Cozar F, Perrino BA, et al. Interaction of calcineurin with a domain of the transcription factor NFAT1 that controls nuclear import. Proc Natl Acad Sci U S A. 1996;93:8907\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2253_CR14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1126\/science.272.5263.892","volume":"272","author":"S Xanthoudakis","year":"1996","unstructured":"Xanthoudakis S, Viola JP, Shaw KT, Luo C, Wallace JD, Bozza PT, et al. An enhanced immune response in mice lacking the transcription factor NFAT1. Science. 1996;272:892\u20135.","journal-title":"Science"},{"key":"2253_CR15","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/0008-5472.CAN-18-3297","volume":"79","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Song Y, Wang R, Hu T, Zhang D, Wang Z, et al. NFAT1-mediated regulation of NDEL1 promotes growth and invasion of Glioma stem-like cells. Cancer Res. 2019;79:2593\u2013603.","journal-title":"Cancer Res"},{"key":"2253_CR16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.molonc.2015.02.004","volume":"9","author":"A Kaunisto","year":"2015","unstructured":"Kaunisto A, Henry WS, Montaser-Kouhsari L, Jaminet SC, Oh EY, Zhao L, et al. NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol. 2015;9:1140\u201354.","journal-title":"Mol Oncol"},{"key":"2253_CR17","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-15-2511","volume":"76","author":"E Shoshan","year":"2016","unstructured":"Shoshan E, Braeuer RR, Kamiya T, Mobley AK, Huang L, Vasquez ME, et al. NFAT1 directly regulates IL8 and MMP3 to promote melanoma tumor growth and metastasis. Cancer Res. 2016;76:3145\u201355.","journal-title":"Cancer Res"},{"key":"2253_CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molcel.2018.10.034","volume":"73","author":"X Jin","year":"2019","unstructured":"Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, et al. Phosphorylated RB promotes cancer immunity by inhibiting NF-kappaB activation and PD-L1 expression. Mol Cell. 2019;73:22\u201335 e26.","journal-title":"Mol Cell"},{"key":"2253_CR19","doi-asserted-by":"crossref","unstructured":"Abu-Ghanem Y, van Thienen JV, Blank C, Aarts MJB, Jewett M, de Jong IJ, et al. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the immediate surgery or surgery after Sunitinib malate in treating patients with metastatic kidney Cancer (SURTIME) trial. BJU Int. 2021;10:27.","DOI":"10.1111\/bju.15625"},{"key":"2253_CR20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13046-019-1044-z","volume":"38","author":"P Fan","year":"2019","unstructured":"Fan P, Zhao J, Meng Z, Wu H, Wang B, Wu H, et al. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. J Exp Clin Cancer Res. 2019;38:47.","journal-title":"J Exp Clin Cancer Res"},{"key":"2253_CR21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"key":"2253_CR22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","volume":"14","author":"M Nishino","year":"2017","unstructured":"Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14:655\u201368.","journal-title":"Nat Rev Clin Oncol"},{"key":"2253_CR23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40:184.","journal-title":"J Exp Clin Cancer Res"},{"key":"2253_CR24","doi-asserted-by":"crossref","first-page":"656908","DOI":"10.3389\/fimmu.2021.656908","volume":"12","author":"D Laha","year":"2021","unstructured":"Laha D, Grant R, Mishra P, Nilubol N. The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment. Front Immunol. 2021;12:656908.","journal-title":"Front Immunol"},{"key":"2253_CR25","doi-asserted-by":"crossref","first-page":"661034","DOI":"10.3389\/fonc.2021.661034","volume":"11","author":"X Zhai","year":"2021","unstructured":"Zhai X, Liu J, Liang Z, Li Z, Liu Y, Huang L, et al. Case report: re-sensitization to Gefitinib in lung adenocarcinoma harboring EGFR mutation and high PD-L1 expression after immunotherapy resistance, which finally transform into small cell carcinoma. Front Oncol. 2021;11:661034.","journal-title":"Front Oncol"},{"key":"2253_CR26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lungcan.2018.11.021","volume":"127","author":"KH Hsu","year":"2019","unstructured":"Hsu KH, Huang YH, Tseng JS, Chen KC, Ku WH, Su KY, et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer. 2019;127:37\u201343.","journal-title":"Lung Cancer"},{"key":"2253_CR27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-019-1137-4","volume":"20","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zeng Y, Liu T, Du W, Zhu J, Liu Z, et al. The canonical TGF-beta\/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Respir Res. 2019;20:164.","journal-title":"Respir Res"},{"key":"2253_CR28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039\u201343.","journal-title":"Science"},{"key":"2253_CR29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1541-7786.MCR-08-0342","volume":"7","author":"M Yoeli-Lerner","year":"2009","unstructured":"Yoeli-Lerner M, Chin YR, Hansen CK, Toker A. Akt\/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res. 2009;7:425\u201332.","journal-title":"Mol Cancer Res"},{"key":"2253_CR30","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1074\/jbc.M116.764407","volume":"292","author":"X Jin","year":"2017","unstructured":"Jin X, Yang C, Fan P, Xiao J, Zhang W, Zhan S, et al. CDK5\/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. J Biol Chem. 2017;292:6269\u201380.","journal-title":"J Biol Chem"},{"key":"2253_CR31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/gutjnl-2019-318362","volume":"69","author":"N Niu","year":"2020","unstructured":"Niu N, Lu P, Yang Y, He R, Zhang L, Shi J, et al. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis. Gut. 2020;69:715\u201326.","journal-title":"Gut"},{"key":"2253_CR32","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.0505575102","volume":"102","author":"J Laganiere","year":"2005","unstructured":"Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V. From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci U S A. 2005;102:11651\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2253_CR33","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688\u201396.","journal-title":"J Clin Oncol"},{"key":"2253_CR34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289\u201396.","journal-title":"J Clin Oncol"},{"key":"2253_CR35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u201324.","journal-title":"N Engl J Med"},{"key":"2253_CR36","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","volume":"13","author":"RH Thompson","year":"2007","unstructured":"Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757\u201361.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2253_CR37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/jcm9020565","volume":"9","author":"MO Grimm","year":"2020","unstructured":"Grimm MO, Leucht K, Grunwald V, Foller S. New first line treatment options of clear cell renal cell Cancer patients with PD-1 or PD-L1 immune-checkpoint inhibitor-based combination therapies. J Clin Med. 2020;9(2):565.","journal-title":"J Clin Med"},{"key":"2253_CR38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40265-020-01327-7","volume":"80","author":"L Hirsch","year":"2020","unstructured":"Hirsch L, Flippot R, Escudier B, Albiges L. Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs. 2020;80:1169\u201381.","journal-title":"Drugs"},{"key":"2253_CR39","doi-asserted-by":"crossref","first-page":"105732","DOI":"10.1016\/j.phrs.2021.105732","volume":"170","author":"Y He","year":"2021","unstructured":"He Y, Luo Y, Huang L, Zhang D, Wang X, Ji J, et al. New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Pharmacol Res. 2021;170:105732.","journal-title":"Pharmacol Res"},{"key":"2253_CR40","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/1535-7163.MCT-11-0907","volume":"11","author":"PB Makhov","year":"2012","unstructured":"Makhov PB, Golovine K, Kutikov A, Teper E, Canter DJ, Simhan J, et al. Modulation of Akt\/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther. 2012;11:1510\u20137.","journal-title":"Mol Cancer Ther"},{"key":"2253_CR41","doi-asserted-by":"crossref","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","volume":"6","author":"G Shayan","year":"2017","unstructured":"Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology. 2017;6:e1261779.","journal-title":"Oncoimmunology"},{"issue":"9","key":"2253_CR42","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/cancers11091318","volume":"11","author":"D Cretella","year":"2019","unstructured":"Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A. PTEN alterations as a potential mechanism for tumor cell escape from PD-1\/PD-L1 inhibition. Cancers (Basel). 2019;11(9):1318.","journal-title":"Cancers (Basel)"},{"key":"2253_CR43","doi-asserted-by":"crossref","first-page":"e2100881","DOI":"10.1002\/advs.202100881","volume":"8","author":"W Xiong","year":"2021","unstructured":"Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X. RRM2 regulates sensitivity to Sunitinib and PD-1 blockade in renal cancer by stabilizing ANXA1 and activating the AKT pathway. Adv Sci (Weinh). 2021;8:e2100881.","journal-title":"Adv Sci (Weinh)"},{"key":"2253_CR44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138.","journal-title":"Nat Immunol"},{"key":"2253_CR45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncb816","volume":"4","author":"S Jauliac","year":"2002","unstructured":"Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol. 2002;4:540\u20134.","journal-title":"Nat Cell Biol"},{"key":"2253_CR46","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1158\/0008-5472.CAN-04-0431","volume":"64","author":"K Holzmann","year":"2004","unstructured":"Holzmann K, Kohlhammer H, Schwaenen C, Wessendorf S, Kestler HA, Schwoerer A, et al. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res. 2004;64:4428\u201333.","journal-title":"Cancer Res"},{"key":"2253_CR47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/172460080702200310","volume":"22","author":"K Zhang","year":"2007","unstructured":"Zhang K, Li N, Chen Z, Shao K, Zhou F, Zhang C, et al. High expression of nuclear factor of activated T cells in Chinese primary non-small cell lung cancer tissues. Int J Biol Markers. 2007;22:221\u20135.","journal-title":"Int J Biol Markers"},{"key":"2253_CR48","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-10-2320","volume":"17","author":"MG Noordhuis","year":"2011","unstructured":"Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, van Zanden JJ, Moerland PD, et al. Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res. 2011;17:1317\u201330.","journal-title":"Clin Cancer Res"},{"key":"2253_CR49","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1158\/0008-5472.CAN-11-4155","volume":"72","author":"K Gerlach","year":"2012","unstructured":"Gerlach K, Daniel C, Lehr HA, Nikolaev A, Gerlach T, Atreya R, et al. Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis. Cancer Res. 2012;72:4340\u201350.","journal-title":"Cancer Res"},{"key":"2253_CR50","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1158\/0008-5472.CAN-12-2424","volume":"72","author":"RR Braeuer","year":"2012","unstructured":"Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012;72:5757\u201366.","journal-title":"Cancer Res"},{"key":"2253_CR51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1146\/annurev.immunol.15.1.707","volume":"15","author":"A Rao","year":"1997","unstructured":"Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707\u201347.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2253_CR52","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/cancers11050681","volume":"11","author":"RV Iyer","year":"2019","unstructured":"Iyer RV, Maguire O, Kim M, Curtin LI, Sexton S, Fisher DT, et al. Dose-dependent Sorafenib-induced immunosuppression is associated with aberrant NFAT activation and expression of PD-1 in T cells. Cancers (Basel). 2019;11(5):681.","journal-title":"Cancers (Basel)"},{"key":"2253_CR53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12964-017-0210-1","volume":"15","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Han S, Cheng W, Wang Z, Wu A. NFAT1-regulated IL6 signalling contributes to aggressive phenotypes of glioma. Cell Commun Signal. 2017;15:54.","journal-title":"Cell Commun Signal"},{"key":"2253_CR54","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","volume":"132","author":"TL Song","year":"2018","unstructured":"Song TL, Nairismagi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood. 2018;132:1146\u201358.","journal-title":"Blood"},{"key":"2253_CR55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","volume":"184","author":"X Wang","year":"2017","unstructured":"Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L, et al. Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 2017;184:7\u201314.","journal-title":"Immunol Lett"},{"key":"2253_CR56","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781\u201390.","journal-title":"J Exp Med"},{"key":"2253_CR57","doi-asserted-by":"crossref","first-page":"C1070","DOI":"10.1152\/ajpcell.00116.2020","volume":"319","author":"HF Li","year":"2020","unstructured":"Li HF, Wu YL, Tseng TL, Chao SW, Lin H, Chen HH. Inhibition of miR-155 potentially protects against lipopolysaccharide-induced acute lung injury through the IRF2BP2-NFAT1 pathway. Am J Physiol Cell Physiol. 2020;319:C1070\u201381.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"19","key":"2253_CR58","doi-asserted-by":"crossref","first-page":"e2012908118","DOI":"10.1073\/pnas.2012908118","volume":"118","author":"P Kar","year":"2021","unstructured":"Kar P, Lin YP, Bhardwaj R, Tucker CJ, Bird GS, Hediger MA, et al. The N terminus of Orai1 couples to the AKAP79 signaling complex to drive NFAT1 activation by local Ca (2+) entry. Proc Natl Acad Sci U S A. 2021;118(19):e2012908118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2253_CR59","doi-asserted-by":"crossref","first-page":"e13217","DOI":"10.1111\/acel.13217","volume":"19","author":"X Jin","year":"2020","unstructured":"Jin X, Zhang S, Ding T, Zhao P, Zhang C, Zhang Y, et al. Testicular Lmcd1 regulates phagocytosis by Sertoli cells through modulation of NFAT1\/Txlna signaling pathway. Aging Cell. 2020;19:e13217.","journal-title":"Aging Cell"},{"key":"2253_CR60","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00125-015-3817-z","volume":"59","author":"K Meyerovich","year":"2016","unstructured":"Meyerovich K, Fukaya M, Terra LF, Ortis F, Eizirik DL, Cardozo AK. The non-canonical NF-kappaB pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responses in vitro. Diabetologia. 2016;59:512\u201321.","journal-title":"Diabetologia"},{"key":"2253_CR61","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.neo.2017.06.002","volume":"19","author":"J Zhu","year":"2017","unstructured":"Zhu J, Li Y, Chen C, Ma J, Sun W, Tian Z, et al. NF-kappaB p65 overexpression promotes bladder Cancer cell migration via FBW7-mediated degradation of RhoGDIalpha protein. Neoplasia. 2017;19:672\u201383.","journal-title":"Neoplasia"},{"key":"2253_CR62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc2290","volume":"8","author":"M Welcker","year":"2008","unstructured":"Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8:83\u201393.","journal-title":"Nat Rev Cancer"},{"key":"2253_CR63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcancer.2015.09.005","volume":"36","author":"W Xu","year":"2016","unstructured":"Xu W, Taranets L, Popov N. Regulating Fbw7 on the road to cancer. Semin Cancer Biol. 2016;36:62\u201370.","journal-title":"Semin Cancer Biol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02253-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02253-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02253-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T08:33:46Z","timestamp":1700123626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02253-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02253-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"assertion":[{"value":"10 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki principles. It was approved by the Animal Use and Care Committees at the Second Xiangya hospital, Central South University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects have written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There were no potential conflicts of interest are disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}